Benefits at a glance.
Bacospore®: Research-backed functional benefits.
Digestive comfort & bowel function
Bacospore® has shown activity relevant to healthy bowel function and intestinal comfort. In a castor oil-induced diarrhoea model, the 200 mg/kg dose reduced wet faecal output and produced 26.6% inhibition of diarrhoea at four hours, indicating potential activity related to intestinal fluid balance and bowel regulation.
Gastric mucosal protection
The strain has also been investigated for gastric mucosal defence and resilience. In an ethanol-induced gastric ulcer model, Bacospore® at 200 mg/kg resulted in approximately 80.4% inhibition of ulcer formation, with the findings supporting further investigation of its effects on gastric mucosal integrity and protection.
Cholesterol & bile acid metabolism
Bacospore® has demonstrated the ability to interact with cholesterol and bile salt systems under laboratory conditions. In an in-vitro assay, cholesterol reduction increased with concentration and reached 97.72% at 1,000 µg/mL, approaching the 99.41% reduction observed with the bile salt reference.
Antioxidant defence
MTCC 25308 has demonstrated free-radical scavenging activity in laboratory testing. In a comparative DPPH assay involving four probiotic Bacillus strains, MTCC 25308 recorded an IC₅₀ of 54.19 µg/mL, showing the strongest antioxidant activity among the strains included in that study.
Collagen protection
Beyond gastrointestinal applications, Bacospore® has been investigated for collagen-protective activity through inhibition of collagenase, an enzyme involved in collagen breakdown. The strain preparation showed a concentration-dependent response, reaching 85.40% collagenase inhibition at 200 µg/mL in an in-vitro assay.
Cellular lipid metabolism
Cell-based research has explored the potential of MTCC 25308 in adipocyte biology and lipid metabolism. In differentiated 3T3-L1 cells, the strain produced a moderate reduction in lipid accumulation together with changes in PPAR-γ expression, while maintaining high cell viability.
Strain-specific preclinical evidence.
The benefit areas presented above are supported by strain-specific laboratory, cellular, and animal research on Bacillus coagulans MTCC 25308, reported across two peer-reviewed publications. Research involving other B. coagulans strains is presented separately as species-level background evidence, ensuring that strain-specific findings are clearly distinguished from broader evidence on the species.
The information presented is based primarily on preclinical research and should not be interpreted as evidence of established clinical efficacy in humans. These statements have not been evaluated by the FDA or EFSA. Bacospore® is not intended to diagnose, treat, cure, or prevent any disease.
